Jasper Therapeutics (JSPR) Price & Analysis

Compare

1,019 Followers

JSPR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.27 - $26.05

Previous CloseN/A

Volume4.28M

Average Volume (3M)233.88K

Market Cap

$41.28M

Enterprise Value$47.75M

Total Cash (Recent Filing)$39.51M

Total Debt (Recent Filing)$2.15M

Price to Earnings (P/E)―

Beta2.65

Next Earnings

Nov 06, 2025

EPS Estimate

-1.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.74

Shares Outstanding27,924,040

10 Day Avg. Volume361,554

30 Day Avg. Volume233,881

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.16

Enterprise Value/Revenue40.67

Enterprise Value/Gross Profit-97.25

Enterprise Value/Ebitda-0.53

Forecast

1Y Price Target

$12.43

Price Target Upside433.48% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Clinical Data And EfficacyThe SPOTLIGHT study's 180 mg cohort showed a 92% complete response rate, a 100% clinical response, and a rapid onset of action without any safety concerns, further supporting briquilimab's safety and efficacy profile.

Safety ProfileBriquilimab continues to demonstrate a favorable safety profile with no dose-limiting toxicities.

Bears Say

Development DelaysThe expected start for the Ph2b CSU study has now been pushed out to mid-'26, placing Jasper ~18-24 months behind the competition.

Manufacturing IssuesSome cohorts in BEACON were impacted by an inactive drug product lot, confounding the results and requiring re-dosing and additional patient enrollment.

Jasper Therapeutics News

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

Citizens JMP lowered the firm’s price target on Jasper Therapeutics (JSPR) to $6 from $12 and keeps an...

4d ago

JSPR

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

TD Cowen acted as sole book running manager for the offering. Published first on TheFly – the ultimate...

7d ago

JSPR

Jasper Therapeutics announces common stock offering, no amount given

Jasper Therapeutics (JSPR) announced that it intends to offer and sell in an underwritten public offering, subject to...

8d ago

JSPR

Jasper Therapeutics Announces $30 Million Public Offering

Jasper Therapeutics ( ($JSPR) ) has provided an announcement. On September 18, 2025, Jasper Therapeutics announced the pricing...

7d ago

JSPR

Jasper Therapeutics price target lowered to $25 from $29 at UBS

UBS lowered the firm’s price target on Jasper Therapeutics (JSPR) to $25 from $29 and keeps a Buy...

1M ago

JSPR

Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline

William Blair analyst Matt Phipps has maintained their neutral stance on JSPR stock, giving a Hold rating on...

1M ago

JSPR

Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures

Jasper Therapeutics, Inc. (JSPR) has disclosed a new risk, in the Innovation / R&D category. Jasper Therapeutics, Inc....

1M ago

JSPR

Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Jasper Therapeutics, retaining the price target of...

1M ago

JSPR

Jasper Therapeutics Reports Promising Q2 2025 Results

Jasper Therapeutics, Inc. ( ($JSPR) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

JSPR

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

“The compelling results we are generating in both CSU and CIndU continue to reinforce our belief that briquilimab...

1M ago

JSPR

Jasper Therapeutics Announces Major Corporate Reorganization

Jasper Therapeutics ( ($JSPR) ) has provided an update. On July 8, 2025, Jasper Therapeutics announced a corporate...

3M ago

JSPR

Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria

Jasper Therapeutics (JSPR) announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately...

3M ago

JSPR

RBC downgrades Jasper Therapeutics on questions about briquilimab

As previously reported, RBC Capital downgraded Jasper Therapeutics (JSPR) to Sector Perform from Outperform with a price target...

3M ago

CLDX

JSPR

Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP

Citizens JMP lowered the firm’s price target on Jasper Therapeutics (JSPR) to $12 from $70 and keeps an...

3M ago

JSPR

JSPR FAQ

What was Jasper Therapeutics’s price range in the past 12 months?

Jasper Therapeutics lowest stock price was $2.27 and its highest was $26.05 in the past 12 months.

What is Jasper Therapeutics’s market cap?

Jasper Therapeutics’s market cap is $41.28M.

When is Jasper Therapeutics’s upcoming earnings report date?

Jasper Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 41 days.

How were Jasper Therapeutics’s earnings last quarter?

Jasper Therapeutics released its earnings results on Aug 13, 2025. The company reported -$1.74 earnings per share for the quarter, missing the consensus estimate of -$1.326 by -$0.414.

Is Jasper Therapeutics overvalued?

According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Jasper Therapeutics pay dividends?

Jasper Therapeutics does not currently pay dividends.

What is Jasper Therapeutics’s EPS estimate?

Jasper Therapeutics’s EPS estimate is -1.19.

How many shares outstanding does Jasper Therapeutics have?

Jasper Therapeutics has 27,924,040 shares outstanding.

What happened to Jasper Therapeutics’s price movement after its last earnings report?

Jasper Therapeutics reported an EPS of -$1.74 in its last earnings report, missing expectations of -$1.326. Following the earnings report the stock price went up 2.02%.

Which hedge fund is a major shareholder of Jasper Therapeutics?

Currently, no hedge funds are holding shares in JSPR

Jasper Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-146.87%

Trailing 12-Months

Asset Growth

-59.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Jasper Therapeutics (JSPR) Earnings & Revenues

Historic Earnings Reports

JSPR Stock 12 Month Forecast

Average Price Target

$12.43

▲(433.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,4.47076923076923,6.181538461538461,7.892307692307693,9.603076923076923,11.313846153846153,13.024615384615386,14.735384615384616,16.446153846153848,18.15692307692308,19.86769230769231,21.57846153846154,23.28923076923077,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,3.503846153846154,4.247692307692308,4.991538461538461,5.735384615384615,6.479230769230769,7.223076923076922,7.966923076923076,8.71076923076923,9.454615384615384,10.198461538461538,10.942307692307692,11.686153846153845,{"y":12.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.76,2.855384615384615,2.9507692307692306,3.046153846153846,3.1415384615384614,3.236923076923077,3.332307692307692,3.4276923076923076,3.523076923076923,3.6184615384615384,3.713846153846154,3.809230769230769,3.9046153846153846,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.97,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >